Loading stock data…
SLDB
$7.13-0.13 (-1.79%)
Market ClosedLast close May 1
Solid Biosciences Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Solid Biosciences Inc. in the Healthcare sector is trading at $7.13. The stock is currently 20% below its 52-week high of $8.87, remaining 15.9% above its 200-day moving average. Technical signals show oversold RSI of 29 and bearish MACD signal, explaining why SLDB maintains its current momentum and trend strength. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 29) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.13
Potential Upside
5%
Whystock Fair Value$7.49
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Mean target$17.08+139.5%
Range$12.00 – $26.00
Fundamentals
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for th...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$806.81M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.58
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-85.60%
Volume
Today's trading volume
980,330
Recent News
Solid Biosciences says interim results reinforce confidence in SGT-003 potential
Solid Biosciences (SLDB) reported updated “positive” interim data from the ongoing Phase 1/2 INSPIRE DUCHENNE clinical trial of SGT-003. The new data, including additional muscle biopsy, serum biomarker, cardiac function, and safety analyses, “add to a growing dataset that suggests the potential of the biological activity of SGT-003 microdystrophin therapy,” the company stated. The interim update was delivered in an oral presentation at the 2026 MDA Annual Meeting on March 11. “SGT-003 has been
Stock Market Today, March 11: Oracle Surges as Markets Weigh Geopolitical Risks
Today, March 11, 2026, Oracle’s earnings beat and solid inflation data stand out as U.S. stocks wobble on oil and war fears.
Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreich’s Ataxia Update
Solid Biosciences (NASDAQ:SLDB) used a presentation at the 2026 Emerging Outlook Biotech Summit to outline its gene therapy-focused pipeline and discuss recent regulatory interactions around its lead Duchenne muscular dystrophy (DMD) program, SGT-003, as well as early progress in Friedreich’s ataxia
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?
Keros Therapeutics sharpens focus on KER-065 for DMD, cuts staff 45%, shelves cibotercept, and plans a phase II trial in Q1 2026 with cash runway into 2028.
JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success
The company has made more than 50 deals for its proprietary technology as it looks forward to a potentially “transformative” year.